Financhill
Sell
49

ORGO Quote, Financials, Valuation and Earnings

Last price:
$3.66
Seasonality move :
-11.35%
Day range:
$3.54 - $3.73
52-week range:
$2.28 - $6.71
Dividend yield:
0%
P/E ratio:
70.39x
P/S ratio:
1.04x
P/B ratio:
1.92x
Volume:
2.2M
Avg. volume:
925.3K
1-year change:
39.02%
Market cap:
$465.6M
Revenue:
$482M
EPS (TTM):
-$0.17

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ORGO
Organogenesis Holdings
$138M $0.14 -20.61% -92.31% $7.00
ATNM
Actinium Pharmaceuticals
-- -$0.36 -100% -7.24% $5.00
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$0.43 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ORGO
Organogenesis Holdings
$3.67 $7.00 $465.6M 70.39x $0.00 0% 1.04x
ATNM
Actinium Pharmaceuticals
$1.42 $5.00 $44.3M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.61 $0.85 $3.5M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.40 -- $22.5M -- $0.00 0% --
OGEN
Oragenics
$4.05 $1.00 $2.9M -- $0.00 0% 1.30x
TOVX
Theriva Biologics
$0.43 $7.00 $3.5M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ORGO
Organogenesis Holdings
-- 0.491 -- 3.28x
ATNM
Actinium Pharmaceuticals
-- -3.250 -- 9.03x
NBY
NovaBay Pharmaceuticals
4.54% -0.941 1.51% 0.75x
NNVC
Nanoviricides
-- -0.642 -- --
OGEN
Oragenics
-- -1.150 -- --
TOVX
Theriva Biologics
-- -3.651 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ORGO
Organogenesis Holdings
$63M -$20.2M -4.5% -5.05% -23.28% -$23.6M
ATNM
Actinium Pharmaceuticals
-- -$16.6M -95.08% -95.08% -12769.14% -$7.6M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
NNVC
Nanoviricides
-- -$2.2M -- -- -- -$2M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Organogenesis Holdings vs. Competitors

  • Which has Higher Returns ORGO or ATNM?

    Actinium Pharmaceuticals has a net margin of -21.74% compared to Organogenesis Holdings's net margin of -11511.11%. Organogenesis Holdings's return on equity of -5.05% beat Actinium Pharmaceuticals's return on equity of -95.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    ORGO
    Organogenesis Holdings
    72.64% -$0.17 $368.1M
    ATNM
    Actinium Pharmaceuticals
    -- -$0.51 $36.4M
  • What do Analysts Say About ORGO or ATNM?

    Organogenesis Holdings has a consensus price target of $7.00, signalling upside risk potential of 90.74%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 252.11%. Given that Actinium Pharmaceuticals has higher upside potential than Organogenesis Holdings, analysts believe Actinium Pharmaceuticals is more attractive than Organogenesis Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    ORGO
    Organogenesis Holdings
    2 0 0
    ATNM
    Actinium Pharmaceuticals
    2 1 0
  • Is ORGO or ATNM More Risky?

    Organogenesis Holdings has a beta of 1.627, which suggesting that the stock is 62.715% more volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.271, suggesting its less volatile than the S&P 500 by 127.061%.

  • Which is a Better Dividend Stock ORGO or ATNM?

    Organogenesis Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organogenesis Holdings pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ORGO or ATNM?

    Organogenesis Holdings quarterly revenues are $86.7M, which are larger than Actinium Pharmaceuticals quarterly revenues of $81K. Organogenesis Holdings's net income of -$18.8M is lower than Actinium Pharmaceuticals's net income of -$15.9M. Notably, Organogenesis Holdings's price-to-earnings ratio is 70.39x while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings is 1.04x versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ORGO
    Organogenesis Holdings
    1.04x 70.39x $86.7M -$18.8M
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$15.9M
  • Which has Higher Returns ORGO or NBY?

    NovaBay Pharmaceuticals has a net margin of -21.74% compared to Organogenesis Holdings's net margin of -49.65%. Organogenesis Holdings's return on equity of -5.05% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    ORGO
    Organogenesis Holdings
    72.64% -$0.17 $368.1M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About ORGO or NBY?

    Organogenesis Holdings has a consensus price target of $7.00, signalling upside risk potential of 90.74%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 40.31%. Given that Organogenesis Holdings has higher upside potential than NovaBay Pharmaceuticals, analysts believe Organogenesis Holdings is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ORGO
    Organogenesis Holdings
    2 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is ORGO or NBY More Risky?

    Organogenesis Holdings has a beta of 1.627, which suggesting that the stock is 62.715% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

  • Which is a Better Dividend Stock ORGO or NBY?

    Organogenesis Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organogenesis Holdings pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ORGO or NBY?

    Organogenesis Holdings quarterly revenues are $86.7M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Organogenesis Holdings's net income of -$18.8M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Organogenesis Holdings's price-to-earnings ratio is 70.39x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings is 1.04x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ORGO
    Organogenesis Holdings
    1.04x 70.39x $86.7M -$18.8M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns ORGO or NNVC?

    Nanoviricides has a net margin of -21.74% compared to Organogenesis Holdings's net margin of --. Organogenesis Holdings's return on equity of -5.05% beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ORGO
    Organogenesis Holdings
    72.64% -$0.17 $368.1M
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About ORGO or NNVC?

    Organogenesis Holdings has a consensus price target of $7.00, signalling upside risk potential of 90.74%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 364.29%. Given that Nanoviricides has higher upside potential than Organogenesis Holdings, analysts believe Nanoviricides is more attractive than Organogenesis Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    ORGO
    Organogenesis Holdings
    2 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is ORGO or NNVC More Risky?

    Organogenesis Holdings has a beta of 1.627, which suggesting that the stock is 62.715% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.749%.

  • Which is a Better Dividend Stock ORGO or NNVC?

    Organogenesis Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organogenesis Holdings pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ORGO or NNVC?

    Organogenesis Holdings quarterly revenues are $86.7M, which are larger than Nanoviricides quarterly revenues of --. Organogenesis Holdings's net income of -$18.8M is lower than Nanoviricides's net income of -$2.2M. Notably, Organogenesis Holdings's price-to-earnings ratio is 70.39x while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings is 1.04x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ORGO
    Organogenesis Holdings
    1.04x 70.39x $86.7M -$18.8M
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
  • Which has Higher Returns ORGO or OGEN?

    Oragenics has a net margin of -21.74% compared to Organogenesis Holdings's net margin of --. Organogenesis Holdings's return on equity of -5.05% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ORGO
    Organogenesis Holdings
    72.64% -$0.17 $368.1M
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About ORGO or OGEN?

    Organogenesis Holdings has a consensus price target of $7.00, signalling upside risk potential of 90.74%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 640.82%. Given that Oragenics has higher upside potential than Organogenesis Holdings, analysts believe Oragenics is more attractive than Organogenesis Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    ORGO
    Organogenesis Holdings
    2 0 0
    OGEN
    Oragenics
    0 1 0
  • Is ORGO or OGEN More Risky?

    Organogenesis Holdings has a beta of 1.627, which suggesting that the stock is 62.715% more volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.

  • Which is a Better Dividend Stock ORGO or OGEN?

    Organogenesis Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organogenesis Holdings pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ORGO or OGEN?

    Organogenesis Holdings quarterly revenues are $86.7M, which are larger than Oragenics quarterly revenues of --. Organogenesis Holdings's net income of -$18.8M is lower than Oragenics's net income of -$2.2M. Notably, Organogenesis Holdings's price-to-earnings ratio is 70.39x while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings is 1.04x versus 1.30x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ORGO
    Organogenesis Holdings
    1.04x 70.39x $86.7M -$18.8M
    OGEN
    Oragenics
    1.30x -- -- -$2.2M
  • Which has Higher Returns ORGO or TOVX?

    Theriva Biologics has a net margin of -21.74% compared to Organogenesis Holdings's net margin of --. Organogenesis Holdings's return on equity of -5.05% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ORGO
    Organogenesis Holdings
    72.64% -$0.17 $368.1M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About ORGO or TOVX?

    Organogenesis Holdings has a consensus price target of $7.00, signalling upside risk potential of 90.74%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1527.91%. Given that Theriva Biologics has higher upside potential than Organogenesis Holdings, analysts believe Theriva Biologics is more attractive than Organogenesis Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    ORGO
    Organogenesis Holdings
    2 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is ORGO or TOVX More Risky?

    Organogenesis Holdings has a beta of 1.627, which suggesting that the stock is 62.715% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.

  • Which is a Better Dividend Stock ORGO or TOVX?

    Organogenesis Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organogenesis Holdings pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ORGO or TOVX?

    Organogenesis Holdings quarterly revenues are $86.7M, which are larger than Theriva Biologics quarterly revenues of --. Organogenesis Holdings's net income of -$18.8M is lower than Theriva Biologics's net income of -$4.3M. Notably, Organogenesis Holdings's price-to-earnings ratio is 70.39x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings is 1.04x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ORGO
    Organogenesis Holdings
    1.04x 70.39x $86.7M -$18.8M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is Apple Stock Not Joining the Broader Market Rally?
Why Is Apple Stock Not Joining the Broader Market Rally?

The S&P 500 has sprinted 4.92% higher so far in…

Will Google Stock Double by 2030?
Will Google Stock Double by 2030?

If you bought Alphabet (NASDAQ: GOOGL) when Gmail launched in…

Why Did David Tepper Sell NVIDIA Stock?
Why Did David Tepper Sell NVIDIA Stock?

In Q1, billionaire David Tepper of Appaloosa Management sold nearly…

Stock Ideas

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 54x

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
49
NKE alert for Jun 28

Nike [NKE] is up 15.29% over the past day.

Buy
81
KTOS alert for Jun 28

Kratos Defense & Security Solutions [KTOS] is up 10.89% over the past day.

Sell
44
GDXU alert for Jun 28

MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 10.89% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock